CS
ABVX

Candriam SCA’s Abivax ABVX Stock Holding History

Candriam SCA’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,061
Closed -$4.02M – 678
2026
Q1 		$4.02M Buy
+36,061
New +$4.27M 0.02% 423

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Candriam SCA's ABVX Position: Q2 2026 in Review

Candriam SCA sold out of Abivax (ABVX) in Q2 2026, closing a stake of 36,061 shares — an estimated $4.02M sold.

Candriam SCA first reported a position in ABVX in Q1 2026 and held it in 1 quarter. The position peaked at $4.02M in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Candriam SCA reported no remaining Abivax position as of Q2 2026 after selling out during the quarter.
  • Candriam SCA sold 36,061 Abivax shares in Q2 2026, an estimated $4.02M.
  • Candriam SCA first reported a position in Abivax in Q1 2026 and held it in 1 quarter.
  • Candriam SCA's Abivax position peaked at $4.02M in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.